Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to shield kidneys during heart surgery

NCT ID NCT05746559

Disease control Sponsor: Alexion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 4 times

Summary

This study tests a single dose of ravulizumab given before heart surgery to see if it can prevent kidney damage and serious kidney problems in people with chronic kidney disease. About 736 adults will take part. The goal is to reduce the risk of major kidney events within 90 days after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

555 people

The number who actually took part.

Started

Apr 2023

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant weighs ≥ 30 kg * Planned non-emergent sternotomy with CPB procedure for the following surgeries: * Multi-vessel CABG * Valve replacement or repair; ascending aorta surgery permitted if combined with aortic valve replacement/repair * Combined CABG and valve surgery; inclusion of single-vessel CABG when combined with valve replacement/repair is permitted * Known CKD for at least 90 days (CKD Stage 3A, 3B, or 4) Exclusion Criteria: * Emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the investigator. * Single-vessel CABG without valve surgery is planned. * Off-pump surgery is planned (eg, surgery without CPB). * Recipient of a solid organ or bone marrow transplantation. * Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization. * Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization. * History of unexplained, recurrent infection. * Any use of KRT or presence of AKI within 30 days of randomization * Use of any complement inhibitors, or plasmapheresis or plasma exchange within the year prior to Screening, or planned use during the course of the study. * Participant is not willing to be vaccinated against N meningitidis or is unwilling to receive prophylactic treatment with appropriate antibiotics , if needed * History of or unresolved N meningitidis infection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome heart disorder acute kidney injury prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac disease Cardiopulmonary bypass Chronic kidney disease CKD

Contacts and locations

Locations

  • Research Site

    Orange, California, 92868, United States

  • Research Site

    San Francisco, California, 94143, United States

  • Research Site

    Stanford, California, 94305, United States

  • Research Site

    Chicago, Illinois, 60637, United States

  • Research Site

    Boston, Massachusetts, 02115, United States

  • Research Site

    Springfield, Massachusetts, 01107, United States

  • Research Site

    Kansas City, Missouri, 64111, United States

  • Research Site

    Rochester, New York, 14621, United States

  • Research Site

    Valhalla, New York, 10595, United States

  • Research Site

    Fargo, North Dakota, 58102, United States

  • Research Site

    Philadelphia, Pennsylvania, 19140, United States

  • Research Site

    Charleston, South Carolina, 29425, United States

  • Research Site

    Dallas, Texas, 75390, United States

  • Research Site

    Charlottesville, Virginia, 22908, United States

  • Research Site

    Richmond, Virginia, 23298, United States

  • Research Site

    Seattle, Washington, 98195, United States

  • Research Site

    Buenos Aires, C1180AAV, Argentina

  • Research Site

    Ciudad de Buenos Aires, C1199ABB, Argentina

  • Research Site

    Ciudad de Buenos Aires, C1428, Argentina

  • Research Site

    Corrientes, W3400AMZ, Argentina

  • Research Site

    Santa Fe, S3000EOM, Argentina

  • Research Site

    Brisbane, 4102, Australia

  • Research Site

    Monash, Australia

  • Research Site

    Murdoch, 6150, Australia

  • Research Site

    Southport, 4215, Australia

  • Research Site

    Belo Horizonte, 30150-221, Brazil

  • Research Site

    Fortaleza, 60430-375, Brazil

  • Research Site

    Recife, 50070-550, Brazil

  • Research Site

    Ribeirão Preto, 14051-140, Brazil

  • Research Site

    Rio de Janeiro, 22270-005, Brazil

  • Research Site

    Salvador, 40301-155, Brazil

  • Research Site

    São José do Rio Preto, 15090-000, Brazil

  • Research Site

    São Paulo, 01323-900, Brazil

  • Research Site

    São Paulo, 04012-180, Brazil

  • Research Site

    São Paulo, 05403-000, Brazil

  • Research Site

    Edmonton, Alberta, T6G 2B7, Canada

  • Research Site

    Winnipeg, Manitoba, R2H 2A6, Canada

  • Research Site

    Saint John, New Brunswick, E2L 4L4, Canada

  • Research Site

    Hamilton, Ontario, L8L 2X2, Canada

  • Research Site

    Kingston, Ontario, K7L 2V7, Canada

  • Research Site

    Toronto, Ontario, M5B 1W8, Canada

  • Research Site

    Montreal, Quebec, H1T 1C8, Canada

  • Research Site

    Montreal, Quebec, H2X 0C1, Canada

  • Research Site

    Montreal, Quebec, H4J 1C5, Canada

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Shanghai, 200080, China

  • Research Site

    Shenzhen, 518036, China

  • Research Site

    Shenzhen, 518053, China

  • Research Site

    Tianjin, 300050, China

  • Research Site

    Zhengzhou, 450007, China

  • Research Site

    Zhengzhou, 450052, China

  • Research Site

    Bordeaux, 33074, France

  • Research Site

    Dijon, 21079, France

  • Research Site

    Montpellier, 34000, France

  • Research Site

    Toulouse, 31076, France

  • Research Site

    Frankfurt am Main, 60590, Germany

  • Research Site

    Giessen, 35392, Germany

  • Research Site

    Halle, 06120, Germany

  • Research Site

    Heidelberg, 69120, Germany

  • Research Site

    Jena, 07747, Germany

  • Research Site

    München, 81377, Germany

  • Research Site

    Trier, 54292, Germany

  • Research Site

    Hong Kong, 999077, Hong Kong

  • Research Site

    Bangalore, 560069, India

  • Research Site

    Bangalore, 560092, India

  • Research Site

    Gurgaon, 122001, India

  • Research Site

    Hyderabad, 500 034, India

  • Research Site

    Mysuru, 570004, India

  • Research Site

    Secunderabad, 500003, India

  • Research Site

    Haifa, 3109601, Israel

  • Research Site

    Haifa, 34362, Israel

  • Research Site

    Bari, 70124, Italy

  • Research Site

    Florence, 50134, Italy

  • Research Site

    Milan, 20138, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Bunkyō City, 113-8431, Japan

  • Research Site

    Chūōku, 104-8560, Japan

  • Research Site

    Kamakura-shi, 247-8533, Japan

  • Research Site

    Kawasaki-shi, 216-8511, Japan

  • Research Site

    Minatoku, 105-8470, Japan

  • Research Site

    Okayama, 700-0804, Japan

  • Research Site

    Sagamihara-shi, 252-0375, Japan

  • Research Site

    Suginami City, 168-0065, Japan

  • Research Site

    Urayasu, 279-0001, Japan

  • Research Site

    Groningen, 9713 GZ, Netherlands

  • Research Site

    Maastricht, 6229 HX, Netherlands

  • Research Site

    Bielsko-Biala, 43-316, Poland

  • Research Site

    Chrzanów, 32-500, Poland

  • Research Site

    Lodz, 91-347, Poland

  • Research Site

    Lodz, 92-213, Poland

  • Research Site

    Poznan, 60-355, Poland

  • Research Site

    Szczecin, 70-111, Poland

  • Research Site

    Tychy, 43-100, Poland

  • Research Site

    Anyang-si, 14068, South Korea

  • Research Site

    Busan, 49241, South Korea

  • Research Site

    Daegu, 42601, South Korea

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seoul, 02841, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 08308, South Korea

  • Research Site

    Seoul, 120-752, South Korea

  • Research Site

    A Coruña, 15006, Spain

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Barcelona, 8035, Spain

  • Research Site

    Córdoba, 14004, Spain

  • Research Site

    Madrid, 28040, Spain

  • Research Site

    Madrid, 28041, Spain

  • Research Site

    Majadahonda, 28250, Spain

  • Research Site

    Navarra, 31190, Spain

  • Research Site

    Seville, 41071, Spain

  • Research Site

    Valencia, 46010, Spain

  • Research Site

    Valladolid, 47003, Spain

  • Research Site

    Hualien City, 970473, Taiwan

  • Research Site

    Kaohsiung City, 83301, Taiwan

  • Research Site

    New Taipei City, 220, Taiwan

  • Research Site

    Taichung, 40447, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 11696, Taiwan

  • Research Site

    Ankara, 06800, Turkey (Türkiye)

  • Research Site

    Antalya, 07100, Turkey (Türkiye)

  • Research Site

    Istanbul, 34303, Turkey (Türkiye)

  • Research Site

    Istanbul, 34846, Turkey (Türkiye)

  • Research Site

    Menemen/Izmir, 35665, Turkey (Türkiye)

  • Research Site

    Odunpazari, 26080, Turkey (Türkiye)

  • Research Site

    Cambridge, CB2 0AY, United Kingdom

  • Research Site

    Clydebank, G81 4DY, United Kingdom

  • Research Site

    London, W12 0HS, United Kingdom

  • Research Site

    Newcastle upon Tyne, NE7 7DN, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.